Shanghai Fosun Pharmaceutical (02196) plans to spend RMB250 million to RMB500 million to repurchase its A-shares.
Shanghai Fosun Pharmaceutical (02196) announced that on November 22, 2026, pursuant to the 2026 A-share repurchase authorization, the 45th meeting of the 10th Board of Directors of the Company deliberated and approved the "Proposal on the A-share Repurchase Plan by Way of Centralized Bidding" (hereinafter referred to as the "A-share Repurchase Plan" or "this Repurchase Plan").
Shanghai Fosun Pharmaceutical (02196) announced that on November 22, 2026, pursuant to the 2026 A-share repurchase authorization, the 45th meeting of the tenth session of the Board of Directors of the Company deliberated and approved the "Proposal on the Plan to Repurchase A-Shares by Way of Centralized Bidding" (hereinafter referred to as the "A-Share Repurchase Plan" or "this Repurchase Plan").
Based on confidence in the development prospects of the Group and recognition of its intrinsic value, and in order to safeguard the interests of the broad base of investors and enhance investor confidence, it is proposed to repurchase the Company's domestically listed RMB ordinary shares (A-shares) by way of centralized bidding.
The repurchase period is 12 months from the date on which the Board of Directors of the Company deliberated and approved this Repurchase Plan, i.e., from November 22, 2026 to November 21, 2027 (inclusive of both the first and last days); if during the repurchase period the Company's A-shares are continuously suspended from trading for more than 10 trading days due to the planning of a major matter, the repurchase period will be extended after the resumption of trading of the A-shares and disclosed in a timely manner.
The total amount of repurchase funds shall be no less than RMB250 million and no more than RMB500 million (both inclusive). The source of repurchase funds shall be own funds and/or self-raised funds (including but not limited to special loans for share repurchases).
The upper limit of the A-share repurchase price is RMB33 per share, which does not exceed 150% of the average trading price of the Company's A-shares over the 30 trading days preceding the date on which the Board of Directors approved this Repurchase Plan. The specific repurchase price will be determined by the management of the Company and/or its authorized persons during the repurchase period, taking into comprehensive account of market conditions, the Company's A-share stock price, and the financial position and operating conditions of the Group.
Related Articles

BAMA TEA (06980) responds to suspension of military procurement qualification: it is a qualification adjustment in a specific field and has no impact on the group's public-facing sales, operations, and core business.

YUM CHINA (09987) repurchased approximately 111,500 shares for approximately US$5.5999 million on November 20.

SUNMI TECH-W (06810): Regarding the Strategic Positioning, Mission, and Vision for the Next Decade
BAMA TEA (06980) responds to suspension of military procurement qualification: it is a qualification adjustment in a specific field and has no impact on the group's public-facing sales, operations, and core business.

YUM CHINA (09987) repurchased approximately 111,500 shares for approximately US$5.5999 million on November 20.

SUNMI TECH-W (06810): Regarding the Strategic Positioning, Mission, and Vision for the Next Decade






